Compare DCX & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCX | DCOY |
|---|---|---|
| Founded | 2009 | N/A |
| Country | China | United States |
| Employees | 1389 | 11 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.2M |
| IPO Year | N/A | N/A |
| Metric | DCX | DCOY |
|---|---|---|
| Price | $0.95 | $7.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 112.1K | ★ 225.6K |
| Earning Date | 05-14-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.53 |
| 52 Week High | $5.68 | $13.51 |
| Indicator | DCX | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 25.60 | 56.07 |
| Support Level | $0.94 | $4.98 |
| Resistance Level | $2.30 | $9.33 |
| Average True Range (ATR) | 0.24 | 1.04 |
| MACD | -0.14 | 0.17 |
| Stochastic Oscillator | 5.10 | 26.56 |
Digital Currency X Technology Inc, formerly Chijet Motor Company Inc is engaged in the development, manufacture, sales, and service of new energy vehicles (NEV), hybrid vehicles and traditional fuel vehicles in China. New energy vehicles refer to plug-in electric vehicles, including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans. The company generates all of its revenue from PRC.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.